HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER
| Autor: | Pedro Nazareth Aguiar Junior, Nora Manoukian Forones, Ricardo Artigiani Neto |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Receptor ErbB-2 Receptor expression Stomach neoplasms Gastroenterology Disease-Free Survival Receptor ErbB2 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Medicine Humans Neoplasia gástricas lcsh:RC799-869 skin and connective tissue diseases Aged Retrospective Studies Aged 80 and over Performance status business.industry Proportional hazards model Cancer Retrospective cohort study Histology Middle Aged medicine.disease Prognosis Immunohistochemistry Surgery Molecular targeted therapy 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis lcsh:Diseases of the digestive system. Gastroenterology Female Terapia de alvo molecular Quimioterapia Drug therapy business |
| Zdroj: | Arquivos de Gastroenterologia v.53 n.2 2016 Arquivos de gastroenterologia Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia instacron:IBEPEGE Arquivos de Gastroenterologia, Volume: 53, Issue: 2, Pages: 62-67, Published: JUN 2016 Arquivos de Gastroenterologia, Vol 53, Iss 2, Pp 62-67 |
| Popis: | Background - Human epidermal growth factor receptor 2 (EGFR2/HER2/ErbB2) is a transmembrane receptor that stimulates cell proliferation when activated. The correlation of HER2 expression with prognosis has been studied in many cancer types. However, its relationship with survival of patients with metastatic gastric cancer remains unknown. Moreover, there is a lack of information on this issue in a Brazilian population. Objective - To assess the proportion of patients whose tumor cells express HER2 and correlate this with clinical characteristics as well as treatment outcomes. Methods - This was a retrospective study. We included adult patients with metastatic gastric cancer treated at an University Hospital between 2011 and 2015. Patients did not receive anti-HER2 therapy. Receptor expression was evaluated by immunohistochemistry. Survival risk factors were assessed individually with univariate Cox regression, and a P value |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|